ALK and non-small cell lung carcinoma: The phase I PROFILE 1001 study investigated crizotinib, a tyrosine kinase inhibitor of ALK, ROS1 and MET, versus platinum-based chemotherapy in patients with ALK-positive NSCLC [138].